NCT07777263
ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)
At risk: Primary completion moved at least 31 days later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Start date: Oct 2026 to Dec 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 66 words
- Primary completion pushed from Oct 2035 to Dec 2035
- Study completion pushed from Oct 2040 to Dec 2040
- Secondary endpoints: details revised at 4 of 10 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
5-year biochemical failure-free survival (bFFS)
Timeframe: 5 years
Secondary (10)
Metastasis-free survival
Overall survival
Prostate cancer-specific mortality
8-year biochemical failure-free survival (bFFS)
Toxicity - Acute
Show 5 moreShow less
Toxicity - Late
Quality of Life - General
Quality of Life - Pain
Quality of Life - Fatigue
Testosterone Recuperation
Arms and interventions
Arm 1 (experimental): 12 months of ADT + RadiotherapyExperimental
Zoladex is given for 12 months instead of 24
Arm 2 (standard of care): 24 months of ADT + RadiotherapyActive comparator
Drugs: ZOLADEX 10.8 mg
Sites
1 site in 1 country
- Jewish General HospitalMontreal, Quebec, Canada